The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-
L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and …

The molecular mechanisms underlying cancer immune escape are a core topic in cancer
immunology research. Cancer cells can escape T cell-mediated cellular cytotoxicity by …

Cancer immunotherapy using anti‐programmed death‐ligand 1 (PD‐L1) antibodies has
been used in various clinical applications and achieved certain results. However, such …

Programmed death-ligand 1 (PD-L1), a critical immune checkpoint ligand, is a
transmembrane protein synthesized in the endoplasmic reticulum of tumor cells and …

Long term immunosuppression is problematic during sepsis. The PD-1 and PD-L1 immune
checkpoint proteins have potent immunosuppressive functions. Recent studies have …

The development and response to treatment of tumor are modulated by inflammation, and
chronic inflammation promotes tumor progression and therapy resistance. This article …

Inside PD-1/PD-L1,2 with their inhibitors - ScienceDirect Skip to main contentSkip to article
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue Search …

Immune checkpoint inhibitors (ICIs) are an expanding class of immunotherapeutic agents
with the potential to cure cancer. Despite the outstanding clinical response in patient …

PD-L1 is an important immune checkpoint protein that can bind to T cells' PD-1 receptor,
thereby promoting immune escape from tumors. In recent years, many researchers have …

Tumor cell–originated events prevent efficient antitumor immune response and limit the
application of anti-PD1 checkpoint immunotherapy. We show that syndecan-1 (SDC1) has a …